Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

Giugliano R. P., Ruff C. T., Rost N. S., Silverman S., Wiviott S. D., Lowe C., ...More

STROKE, vol.45, no.8, pp.2372-2378, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 45 Issue: 8
  • Publication Date: 2014
  • Doi Number: 10.1161/strokeaha.114.006025
  • Journal Name: STROKE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2372-2378
  • Keywords: anticoagulant, atrial fibrillation, cerebral hemorrhage, stroke, ORAL ANTICOAGULANTS, THERAPY, STROKE, METAANALYSIS, INHIBITION, PREVENTION, DABIGATRAN, INTENSITY
  • Gazi University Affiliated: Yes


Background and Purpose-The once-daily oral factor Xa inhibitor, edoxaban, is as effective as warfarin in preventing stroke and systemic embolism while decreasing bleeding in a phase III trial of patients with atrial fibrillation at moderate-high stroke risk. Limited data regarding cerebrovascular events with edoxaban were reported previously.